González-Rodríguez KT, Vargas-Ruiz ÁG, López-Karpovitch X

Language: Spanish
References: 26
Page: 425-429
PDF size: 80.14 Kb.

ABSTRACT

Background: in Mexico published casuistry concerning hairy cell leukemia (HCL) is limited. Objective: to describe the therapeutic response and survival of patients with HCL attended in a third level public institution. Methods: patient’s data with HCL diagnosis registered between January 1989 - December 2009 were analyzed. Results: twenty three patients fulfilled HCL diagnosis criteria. Median age was 44 years (range 23-75 years) and median follow-up of the cohort was 1,877 days (range 1-8,462 days). First line treatment varied along time finding complete response (CR) and partial response (PR) rates of 77.3 and 18.2%, respectively. Of all therapeutic modalities employed cladribine induced the highest response rate. Survival at 1,877 days was 82.6%. At last follow-up 65.2% of patients remain alive, 13 in CR and 2 in PR; 4 died (CR = 2, PR = 1, active disease = 1) and 4 were lost during follow-up. Conclusion: this study which included more patients than previous single-institution Mexican series confirm the chronic clinical behavior of HCL and that purine analogs are corner stone in the treatment of patients suffering HCL.

REFERENCES

1. Golomb HM. Fifty years of hairy cell leukemia treatments. Leukemia & Lymphoma. 2011;52 Suppl 2:3-5.

2. Swerdlow SH, Campo E, Harris NL, et al., eds. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 188-90.

3. Tadmor T, Polliack A. Unusual clinical manifestations, rare sites of involvement, and the association of other disorders with hairy cell leukemia. Leukemia & Lymphoma. 2011;52 Suppl 2:57-61.

4. Ellis E, Moormeier JA, Golomb H. The treatment of hairy cell leukemia: a review. Leukemia & Lymphoma. 1990;1:11-85.

5. Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leukemia & Lymphoma. 2011;52 Suppl 2:18-20.

6. Quesada JR, Rueben J, Manning JT, Hersh E, Gutterman JU. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med. 1984;310:15-8.

7. Kreitman RJ, Polliack A, Grever M. Treatment of hairy cell leukemia in its second half-century: an International Conference on Hairy Cell Leukemia at the National Institutes of Health, April 26-27, 2010, Bethesda, MD. Leukemia & Lymphoma. 2011;52:1-2.

8. Else M, Dearden C, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leukemia & Lymphoma. 2011;52 Suppl 2:75-8.

9. Golomb HM. Fifty years of hairy cell leukemia treatments. Leukemia & Lymphoma. 2011;52 Suppl 2:3-5.

10. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107:4658-62.

11. Zinzani P, Pellegrini C, Stefoni V, et al. Hairy cell leukemia. Evaluation of the long-term outcome in 121 patients. Cancer. 2010;15:4788-92.

12. Ruiz-Argüelles G, Cantú-Rodríguez O, Gómez-Almaguer D, et al. Hairy cell leukemia is infrequent in Mexico and has a geographic distribution. Am J Hematol. 1996;52:316-8.

13. Frassoldati A, Lamparelli T, Federico M, et al., for the Italian Cooperative Group for Hairy Cell Leukemia. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leukemia & Lymphoma. 1994;13:307-16.

14. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med. 1978;89:677-83.

15. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairycell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-21.

16. Saven A, Buriani C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918-26.

17. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-6.

18. Ruiz-Delgado GJ, Tarín-Arzaga LC, Alarcón-Urdaneta C, Calderón- García J, Gómez-Almaguer D, Ruiz-Argüelles GJ. Treatment of hairy cell leukemia: long-term results in a developing country. Hematology. 2012;17(3):140-3.

19. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer. 1981;47:2066-76.

20. Ratain M, Vardiman J, Barker C, Golomb H. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer. 1988;62:2420-4.

21. Rai KR, Davey F, Peterson B, et al. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term followup result of study by cancer and leukemia group B. Leukemia. 1995;9: 1116-20.

22. Golomb HM, Fefer A, Golde DW, et al. Sequential evaluation of alpha-2binterferon treatment in 128 patients with hairy cell leukemia. Semin Oncol. 1987;14:13-7.

23. Hagberg H, Alm G, Björkholm M, et al. Alpha interferon treatment of patients with hairy cell leukemia. Scand J Haematol. 1985;35:66-70.

24. Ratain MJ, Golomb HM, Vardiman JW, et al. Relapse after interferon alfa-2b therapy for hairy cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988;6:1714-21.

25. Damasio E, Clavio M, Masoudi B, et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur J Haematol. 2000;64:47-52.

26. Golomb HM, Mintz U. Treatment of hairy cell leukemia (leukemic reticuloendotheliosis) II. Chlorambucil therapy in postsplenectomy patients with progressive disease. Blood. 1979;54:305-9.